EGFR and non-small cell lung carcinoma: We previously examined this scenario using two NSCLC cell lines (Mancini et al, 2015): patient‐derived H1975 cells expressing a double mutant of EGFR, L858R, and T790M, and the PC9ER cell line, a derivative of PC9 (del746‐750 EGFR), which acquired the T790M mutation (de Bruin et al, 2014).